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In recent years, the study of the peroxisome proliferators activated receptor gamma (PPAR-γ) as a potential target for cancer
prevention and therapy has gained a strong interest. However, the overall biological significance of PPAR-γ in cancer development
and progression is still controversial. While many reports documented antiproliferative effects in human cancer cell and animal
models, several studies demonstrating potential tumor promoting actions of PPAR-γ ligands raised considerable concerns about
the role of PPAR-γ in human cancers. Controversy also exists about the role of PPAR-γ in human pancreatic cancers. The current
review summarizes the data about PPAR-γ in pancreatic cancer and highlights the biologically relevant interactions between the
cyclooxygenase and PPAR system.
Copyright © 2008 Guido Eibl. This is an open access article distributed under the Creative Commons Attribution License, which
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Despite advances in surgical techniques, imaging modalities,
and intensive care, pancreatic cancer is still an almost
universally lethal disease with annual mortality figures
virtually equaling incidence numbers. An estimated number
of 37 170 patients hse been diagnosed with pancreatic cancer
in 2007, and 33 370 patients have succumbed to that disease
in the same year [1]. Absence of specific symptoms, lack
of early detection markers, aggressive tumor growth, and
virtual resistance to conventional chemo- and radiotherapy
conspire to culminate in a median overall survival of less
than nine months. Currently, surgical removal of the tumor
offers the only hope of long-term survival with 5-year
survival rates approaching 25–30% in large-volume centers
in the US [2]. Although an adjuvant treatment regimen
after surgical resection seems to prolong survival, the precise
treatment protocol including drug-of-choice is still debated
and the focus of several ongoing clinical trials [3]. Only a
disappointing 10–15% of patients at the time of diagnosis are
candidates for surgical resection and even patients who have
undergone “curative” resection often die of recurrent tumor.
The majority of pancreatic cancer patients unfortunately
present with locally advanced or metastatic tumors which
render them ineligible for surgical resection. Gem-citabine,
an S-phase nucleoside cytidine analog, has been the stan-
dard chemotherapeutic drug for locally advanced and
metastatic pancreatic cancer for more than ten years, but
the improvement of overall survival is unacceptably small,
often approaching only a few weeks [4]. Currently, sev-
eral trials are underway that investigate gemcitabine-based
combination therapiesin patients with advanced pancreatic
cancers. Capecitabine, an oral fluoropyrimidine carbamate
and 5-fluorouracil prodrug, and erlotinib, an inhibitor of
the epidermal growth factor receptor, are two promising
agents which seem to improve survival in combination with
gemcitabine compared to gemcitabine monotherapy [4]. The
encouraging results from a large, double-blind, placebo-
controlled, international phase III trial led to the approval of
erlotinib for the treatment of locally advanced and metastatic
pancreatic cancer in combination with gemcitabine [5].
Although certainly noteworthy, the improvement of over-
all survival with the combination regimen, however, was
only marginal compared to gemcitabine monotherapy [5],
strongly emphasizing the need for the identification of novel
targets and the development of more efficacious therapeutic
agents.
Although several environmental risk factors for the
development of pancreatic cancers, including tobacco smok-
ing and dietary factors, have been described, detailed insights
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into the pathogenetic mechanisms are virtually lacking
[6]. Dietary intake of high-caloric, high-fat diets with
ensuing obesity and metabolic syndrome has been correlated
with an increased risk of pancreatic cancer [7, 8]. An
important molecule in fatty acid sensing and metabolism
is the peroxisome proliferator activated receptor gamma
(PPAR-γ), a member of the nuclear receptor superfamily
that functions as a ligand-activated transcription factor [9].
There is now a large body of evidence demonstrating an
important role of PPAR-γ in the metabolic syndrome [10–
13]. The thiazolidinedione (TZD) class of PPAR-γ ligands
has been used for the treatment of hyperglycemia and
insulin resistance in type 2 diabetes for the past ten years
[14]. In addition, TZDs may also show beneficial effects
on cardiovascular complications associated with type 2
diabetes and the metabolic syndrome [14–17]. More recently,
the role of PPAR-γ in various human cancers has been
studied. There is now strong evidence that PPAR-γ is
overexpressed in a variety of cancers, including colon, breast,
prostate, stomach, lung, and pancreas [18–20]. However, the
biological significance of PPAR-γ is still controversial [21,
22]. Although several reviews highlight the antiproliferative
actions of PPAR-γ ligands in cell culture and animal models
of human cancers [23, 24], more recent studies illustrating
a tumor-promoting effect of PPAR-γ, in particular in colon
and breast cancer models, raise considerable concern about
the significance and safety of PPAR-γ ligands as anticancer
drugs [25–29]. This review will summarize and discuss the
data concerning the role of PPAR-γ in pancreatic cancer.
2. PPAR-GAMMA IN PANCREATIC CANCER
Reports from several groups have shown that the thiazo-
lidinedione (TZD) class of PPAR-γ ligands attenuates the
growth of pancreatic cancer cells in vitro by induction
of terminal differentiation and G1 phase cell cycle arrest
[30, 31], and by an increase in apoptotic cell death [32].
Furthermore, thiazolidinediones attenuated pancreatic can-
cer cell migration and invasion by modulation of actin
organization and expression of matrix metalloproteinase-2
and plasminogen activator inhibitor-1, respectively [33, 34].
However, many growth-inhibitory effects of PPAR-γ ligands
are independent of PPAR-γ [35]. To date, several non-
PPAR-γ targets have been implicated in the antitumor
activities of certain TZDs, for example, troglitazone and
ciglitazone, including intracellular Ca2+ stores, mitogen-
activated protein kinases, cyclin-dependent kinase inhibitors
p27kip1 and p21WAF/CIP1, the tumor suppressor protein
p53, and Bcl-2 family members [36]. There is increasing
evidence that TZDs directly affect mitochondrial function
which impairs oxidative respiration leading to increased
reactive oxygen species (ROS) production and ATP deple-
tion, which in turn can activate AMP kinase [37]. An
increase in ROS and activation of AMP kinase can lead to
PPAR-γ independent reduction in inflammation and cell
growth [37]. In addition, it has been shown in pancre-
atic cancer cells that 2-cyano-3,12-dioxooleana-1,9-dien-28-
imidazolide (CDDO-Im), a partial PPAR-γ agonist, induces
apoptosis directly by targeting mitochondrial glutathione
[38]. Furthermore, 3,3′-diindolylmethane (DIM), another
PPAR-γ agonist, induced apoptotic cell death in pancreatic
cancer cells through activation of the endoplasmic stress
response [39]. Overall, the potential to elicit PPAR-γ-
independent effects may be ligand- and cell context-
dependent. Our own studies have demonstrated that PPAR-γ
is expressed in the nucleus of six human pancreatic cancer
cells and that treatment of these cells in vitro with 15-deoxy-
Δ12,14-prostaglandin J2 (15-PGJ2) and ciglitazone dose- and
time-dependently decreases cell growth by induction of
caspase-3-dependent apoptosis [40]. In addition to their
antiproliferative actions, both ligands, 15-PGJ2 and cigli-
tazone, reduced the invasive capacity of pancreatic cancer
cells in vitro by a PPAR-γ-mediated decrease of urokinase-
type plasminogen activator and elevation of plasminogen
activator inhibitor-1 expression that resulted in an overall
reduction in urokinase activity [41]. Taken together, there
is a strong evidence today from cell culture models that
PPAR-γ ligands potently reduce the growth of human
pancreatic cancer cells. The discrepancy of the reported
underlying mechanisms, however, may be caused by the use
of different cell lines, culture conditions, and experimental
settings. In contrast to the notion of PPAR-γ ligands being
potent antitumor drugs in pancreatic cancers, we have
reported that treatment of human pancreatic cancer cells
in vitro with 15-PGJ2 and troglitazone dose-dependently
increases the secretion of the vascular endothelial growth
factor (VEGF), which is widely recognized as a potent
stimulus for tumor angiogenesis [42]. In addition, the
culture medium of troglitazone-treated human pancreatic
cancer cells enhanced migration of endothelial cells, another
step in the angiogenic cascade (own finding). These findings
are already observed at submicromolar concentrations of
the PPAR-γ ligands, which are usually considerably lower
than the typical ligand concentrations needed for the
antiproliferative effects in pancreatic cancer cells. Our in
vitro data suggest that PPAR-γ ligands may have a tumor-
promoting effect in vivo by enhancing tumor angiogenesis.
Although the precise role of PPAR-γ in tumor angiogenesis
is still debated and controversial, there is accumulating
evidence that activation of PPAR-γ stimulates VEGF pro-
duction and neoangiogenesis also in other cell models
[43, 44].
In addition to the effects of PPAR-γ ligands on the growth
of established pancreatic cancers in preclinical cell culture
and xenograft mouse models, dietary intake of 800 ppm
pioglitazone for 22 weeks correlated with an improved serum
lipid profile and a decreased incidence and multiplicity of
pancreatic tumors in the N-nitrosobis(2-oxopropyl)amine
(BOP) model of pancreatic carcinogenesis in Syrian golden
hamsters, suggesting a potential chemopreventive role of
TZDs [45].
There are very few data concerning the significance of
PPAR-γ in clinical pancreatic cancer specimens. In a recent
study, PPAR-γ was expressed in the majority of human pan-
creatic cancer specimens, positively correlated with higher
tumor stage and grade, and interestingly was associated
with shorter patient survival, suggesting a potential role in
pancreatic cancer progression [20].
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Figure 1: Possible interactions between the COX-2 and PPAR-γ
pathways: polyunsaturated fatty acids (PUFAs) are substrates for
cyclooxygenase-2 (COX-2) enzymes leading to the formation of
various prostaglandins (PGs). Certain PUFAs and PGs can also
activate PPAR-γ. Selective and nonselective COX-2 inhibitors (COX
Inh) block PG formation by COX-2 but can also at higher
concentrations activate PPAR-γ. Solid arrows indicate activation;
dashed arrow indicates metabolic pathway; blocked arrow indicates
inhibition.
3. INTERACTION BETWEEN THE PPAR-GAMMA
AND COX-2 PATHWAYS
Besides the TZD class of antidiabetic drugs, various intra-
cellular lipids and lipid mediators are capable of activating
PPAR-γ. Among those, polyunsaturated fatty acids (e.g.,
arachidonic acid (AA) and eicosapentaenoic acid (EPA))
and eicosanoids (e.g., 15-deoxy-Δ12,14-prostaglandin J2 (15-
PGJ2)) are also substrates and products, respectively, of intra-
cellular cyclooxygenase (COX) enzymes strongly suggesting
relevant interactions between the PPAR and COX pathways
(see Figure 1).
3.1. COX products as PPAR-γ activators
COX activity leads to the formation of an unstable hydroxy-
endoperoxide, prostaglandin H2, which can be further
converted to various prostanoid species by tissue specific
isomerases [46]. While parent prostaglandins (e.g., PGE2,
PGF2α, and PGD2) transduce their signals through binding
to G-protein coupled cell surface receptors [47], cyclopen-
tenone prostanoids (e.g., PGJ2) are known ligands of PPAR-γ
[48]. In fact, there is evidence suggesting that COX-2 is
preferentially located on the nuclear membrane allowing
cyclopentenone prostaglandins to directly enter the nucleus
and bind to ligand-activated transcription factors [49]. In
this regard, human pancreatic cancer cells seem to express
COX-2 preferentially in a perinuclear localization [50]. 15-
deoxy-Δ12,14-prostaglandin J2 (15-PGJ2), a nonenzymatically
formed dehydration product of PGD2, is detectable in
COX-2 expressing human pancreatic cancer cells (own
observation) and able to activate PPAR-γ in these cells
[42]. Furthermore, a selective COX-2 inhibitor at a con-
centration that inhibits COX-2 activity and consequently
prostanoid production reduces PPAR-γ activity, presumably
by decreasing the levels of cyclopentenone prostaglandins
(own observation).
3.2. COX substrates as PPAR-γ activators
Certain polyunsaturated fatty acids (PUFAs) (e.g., arachi-
donic acid (AA; 20 : 4 n−6) and eicosapentaenoic acid (EPA;
20 : 5 n−3)) are substrates for COX enzymes and also known
PPAR-γ ligands [51]. Both PUFAs are released from the sn-
2 position of major membrane phospholipids by phospho-
lipase A2 (PLA2) enzymes, particularly by the cytoplasmic
PLA2, which upon activation seems to preferentially locate
to the nuclear membrane [52, 53]. Once released, the PUFAs
can be metabolized by COX enzymes or enter the nucleus
to activate PPAR-γ. Our own studies demonstrated that
EPA decreased the growth of human pancreatic cancer cells
through COX-2 dependent and independent mechanisms
(manuscript in press). The COX-2 independent mechanism
involved activation of PPAR-γ by EPA as the growth-
inhibitory effect of EPA was abolished by a pharmacological
PPAR-γ antagonist. Furthermore, EPA and to a lesser extent
AA can activate PPAR-γ transcriptional activity in human
pancreatic cancer cells (own observation). This effect is less
pronounced in pancreatic cancer cells that express COX-2
presumably because EPA is rapidly metabolized by COX-2 in
these cells. The overall efficacy of PUFAs to activate PPAR-γ
may therefore be dependent on the cellular expression and
activity of COX-2.
3.3. COX inhibitors as PPAR-γ activators
In addition to COX-2 substrates and products, certain
nonselective and selective COX-2 inhibitors have also been
shown to activate PPAR-γ independent of their ability
to inhibit COX-2 enzymatic activity [54], although the
precise molecular mechanisms are still unknown. There is a
compelling evidence today that the inducible COX-2 isoform
plays an important role in pancreatic cancer development
and growth and that selective COX-2 inhibitors may be
efficacious for pancreatic cancer prevention and therapy
[50]. Our own studies demonstrated that dietary intake of
a selective COX-2 inhibitor delayed the progression of rec-
ognized pancreatic cancer precursor lesions in a genetically
engineered mouse model of pancreatic cancer development
[55]. Furthermore, a selective COX-2 inhibitor decreased
the growth of COX-2 positive human pancreatic cancers
in a xenograft mouse model by induction of apoptosis
in cancer cells and by inhibition of tumor angiogenesis
[42]. In contrast, the selective COX-2 inhibitor enhanced
the growth of xenografted human pancreatic cancers that
lacked or had very little COX-2 protein expression. This
tumor-promoting effect was associated with an increase
in intratumoral VEGF levels and tumor angiogenesis [42].
Additional studies showed that the tumor-enhancing effect
of the selective COX-2 inhibitor in COX-2 negative or weakly
COX-2 expressing human pancreatic cancers was abolished
by GW9662, an irreversible pharmacological PPAR-γ antag-
onist, suggesting biologically important interactions between
the COX-2 inhibitor and PPAR-γ [42]. Further studies
demonstrating enhanced PPAR-γ binding activity in tumors
that were treated with a selective COX-2 inhibitor confirmed
that interaction [42]. The findings obtained in vivo were
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corroborated by in vitro experiments. Human pancreatic
cancer cells treated with relatively high concentrations of
selective COX-2 inhibitors showed an increased production
and secretion of VEGF, which was inhibited by a pharmaco-
logical PPAR-γ antagonist and a dominant-negative PPAR-γ
receptor [42]. Additionally, the selective COX-2 inhibitor at
that concentration stimulated PPAR-γ transcriptional and
DNA-binding activities [42]. These data clearly indicated
that a biologically significant interaction between selective
COX-2 inhibitors and PPAR-γ exists and that activation
of PPAR-γ by these drugs may have detrimental, that is
tumor-promoting, effects on pancreatic cancer growth. It
is important to note that the tumor-promoting effects of
selective COX-2 inhibitors were only observed at relatively
high concentrations (much higher than needed to inhibit
COX-2 enzymatic activity) in tumors that had no or only
very little COX-2 expression [42]. Although the selective
COX-2 inhibitor stimulated VEGF production by pancreatic
cancer cells through a PPAR-γ mediated mechanism also in
COX-2 expressing pancreatic cancers, the potential proan-
giogenic and tumor-promoting effect in COX-2 positive
cancers was masked by a significant reduction of COX-2
generated proangiogenic and protumorigenic prostanoids
[42].
4. CONCLUSION
While several in vitro studies demonstrate that PPAR-γ acti-
vation decreases pancreatic cancer cell growth, the finding
that PPAR-γ ligands can stimulate VEGF production by
pancreatic cancer cells raises serious concerns that PPAR-γ
activation in vivo may lead to enhanced angiogenesis and
tumor growth. Further detailed studies using pancreatic
cancer animal models and specific PPAR-γ ligands are neces-
sary to evaluate possible proangiogenic and protumorigenic
properties of PPAR-γ activation in vivo. Unfortunately, infor-
mation about the role of PPAR-γ in pancreatic carcinogenesis
is almost nonexistent. The use of the recently developed
genetically engineered mouse models of pancreatic cancer
development that closely recapitulate our current knowledge
of pancreatic cancer development on a histological and
genetic level should shed some needed insights into the role
of PPAR-γ in pancreatic carcinogenesis.
There is now clear evidence of a biologically relevant
interaction between the COX and PPAR-γ pathways. Our
data suggest that activation of PPAR-γ by selective and
nonselective COX-2 inhibitors may have tumor-promoting
effects in vivo by enhancing tumor angiogenesis. The effect of
COX-2 inhibitors on PPAR-γ activation seems to be observed
only at relatively high concentrations of the inhibitors
and the overall biological phenotype of that interaction is
dependent on the cellular expression and activity of the
COX-2 protein. Although the role of PPAR-γ in pancreatic
cancer development and growth has begun to be elucidated
in recent years, a precise knowledge of molecular targets
downstream of PPAR-γ, a more comprehensive elucidation
of PPAR-γ-independent actions of PPAR-γ ligands, and a
detailed understanding of crosstalks between PPAR-γ and
other intracellular signaling pathways seem to be absolutely
necessary and needed to eventually clarify the role of PPAR-γ
in human cancer development and progression.
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